CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 322 enrolled
Drug / intervention
placebo +3 moredrug
Likely dose
ustekinumab 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01008995
NCT01008995Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis

Centocor, Inc.·interventional·Posted Nov 6, 2009·Updated Nov 11, 2013

In Brief

A Phase 3 clinical trial evaluating placebo and ustekinumab for Psoriasis. Completed, enrolled 322 participants across 9 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 6, 2009
Enrollment StartOct 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.7 years ago

Interventions

placebodrug

Subcutaneous injection at Week 0 and 4

ustekinumabdrug

45 mg subcutaneous injection at Week 12 and 16

placebodrug

Subcutaneous injection at Week 12

ustekinumabdrug

45 mg subcutaneous injection at Week 0, 4 and 16